Kv3 Channel Modulators for Neuropathic Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic pain, particularly neuropathic pain, lack effective alternatives to opioids that offer good efficacy with reduced side effects, tolerance, and risk of dependence, and there is a need for modulators targeting Kv3 channels to address the underlying neuronal hyperexcitability.
Innovation Solution
Development of modulators for Kv3.1 and/or Kv3.2 and/or Kv3.3 channels, specifically compounds of formula (I) or their pharmaceutically acceptable salts, solvates, and derivatives, for use in pharmaceutical compositions to treat pain by modulating these channels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioids are used to treat chronic pain, then pain relief efficacy is improved, but side effects, tolerance, and risk of dependence increase
Solution Approach 1:
The patent changes the pharmacological target parameter from opioid receptors to Kv3 potassium channels. By targeting a different ion channel system involved in neuronal excitability, the invention seeks to achieve pain relief through a different mechanism that does not carry the same risks of dependence and tolerance associated with opioid receptor activation.
2Adaptability or versatility
If Kv3 channel modulators are developed, then new mechanism for pain treatment is achieved, but lack of selective compounds and understanding of channel function remains
Solution Approach 1:
The patent segments the Kv3 channel family into distinct subtypes (Kv3.1, Kv3.2, Kv3.3, Kv3.4) with different tissue distributions and functional roles. This segmentation allows for the development of subtype-selective modulators that can target specific neuronal populations involved in pain processing while sparing other functions, thereby reducing off-target effects and complexity.
3Reliability
If broad-spectrum Kv3 channel inhibitors are used, then pain relief may be achieved, but neuronal hyperexcitability control and side effect profile remain uncertain
Solution Approach 1:
The patent applies local quality by targeting Kv3 channels in specific neuronal populations and brain regions involved in pain processing, rather than broadly inhibiting all Kv3 channels throughout the body. This region-specific and cell-type-specific modulation allows for pain relief while preserving Kv3 channel function in other neurons where it is critical for normal physiology, thereby reducing side effects.
Data Source
AI summary
The present invention provides a modulator of Kv3.1 and/or Kv3.2 and/or Kv3.3 channels for use in the prophylaxis or treatment of pain. Modulators for use in the prophylaxis or treatment of pain include compounds of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof and/or derivative thereof: